Risk factor analysis of hypersensitivity reactions to abacavir

Clinical Therapeutics

Volumn 24, Issue 4, 2002, Pages 565-573

  Symonds, William ^a,c   Cutrell, Amy ^a   Edwards, Mark ^a   Steel, Helen ^b   Spreen, Bill ^a   Powell, Gwendolyn ^a   McGuirk, Sue ^b   Hetherington, Seth ^a  

^a GLAXOSMITHKLINE   (United States)

^b GLAXOSMITHKLINE   (United Kingdom)

^c G1axoSmithKline   (United States)

Author keywords

Abacavir; Adverse effects; Drug hypersensitivity; Nucleoside reverse transcriptase inhibitor; Risk factors

Indexed keywords

ABACAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; DEMOGRAPHY; ETHNIC DIFFERENCE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; INCIDENCE; INFANT; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NEGRO; PROGNOSIS; RISK FACTOR; STATISTICAL ANALYSIS; STATISTICAL MODEL;

EID: 0036246069     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(02)85132-3     Document Type: Article

References (8)

1. Unique intracellular activation of the potent anti-human immunodeficiency virus agent 1592U89
2. 1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activity
3. Idiosyncratic drug reactions: The reactive metabolite syndromes
4. Hypersensitivity reactions during therapy with abacavir: Clinical presentation and risk factors
5. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
6. Adverse events from drug therapy for human immunodeficiency virus disease
7. HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients
8. Randomized trial of abacavir (ABC) in combination with indinavir (IDV) and efavirenz (EFV) in HIV-infected patients (Pts) with nucleoside analog experience (NRTI exp)